145672-81-7

Basic information

• Product Name: CETRORELIX
• Synonyms: D 20761;D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N5-(aminocarbonyl)-D-ornithyl-L-leucyl-L-arginyl-L-prolyl-, acetate (salt);Ns 75a;Sb 075 acetate;Cetrotid;Ovurelix;N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N5-(aminocarbonyl)-D-ornithyl-L-leucyl-L-arginyl-L-prolyl-D-alaninamide acetic acid salt
• CAS NO: 145672-81-7
• Molecular Formula: C70H92ClN17O14.C2H4O2
• Molecular Weight: 1491.11
• Product Categories: Amines, Aromatics, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 145672-81-7.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• Density: 1.42 g/cm³
• Storage Temp.: ?20°C
• Solubility: methanol: soluble10%
• CAS DataBase Reference: CETRORELIX(CAS DataBase Reference)
• NIST Chemistry Reference: CETRORELIX(145672-81-7)
• EPA Substance Registry System: CETRORELIX(145672-81-7)

Safety Data

• Statements: 60-63
• Safety Statements: 22
• WGK Germany: 3
• Hazardous Substances Data: 145672-81-7(Hazardous Substances Data)

Usage

Description

Cetrorelix is a synthetic peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) with a high affinity for the receptor, characterized by a Kd value of 0.2 nM for radioligand binding to murine LTKcells expressing human GnRHR. It effectively inhibits the activation of hGnRHR and the downstream signaling pathways, making it a potent therapeutic agent for various conditions. Cetrorelix is also known as the acetic acid salt and is recognized for its role in treating infertility and hormone-sensitive cancers.

Uses

Used in Oncology:
Cetrorelix is used as a therapeutic agent for the treatment of blood cancers such as multiple myeloma (MM). It is employed to study its safety, mechanism of action, metabolism, and efficacy in this context, focusing on its impact on physiological processes and malignancies involving luteinizing hormone releasing hormone receptor signaling pathways, including steroidogenesis.
Used in Reproductive Medicine:
Cetrorelix is utilized in formulations to prevent ovulation during in vitro fertilization (IVF) procedures, thus playing a crucial role in fertility treatments. It has been shown to reduce tumor volume and decrease serum luteinizing hormone levels in a human epithelial ovarian cancer mouse xenograft model, highlighting its potential in managing hormone-sensitive conditions.
Used in Cancer Treatment:
Cetrorelix is used to protect primordial follicles (PMF) in mouse ovaries from damage induced by cyclophosphamide, a chemotherapy drug. It has demonstrated the ability to increase PMF survival by 65% to 86% compared to 46% with a saline control, showcasing its potential in mitigating the side effects of cancer treatments on reproductive health.
Used in Hormone-Sensitive Cancer Treatments:
As a GnRH antagonist, Cetrorelix is used for the treatment of hormone-sensitive cancers of the prostate and breast. It helps in managing the hormonal aspects of these cancers by blocking the effects of gonadotropin-releasing hormone, thereby potentially slowing down cancer progression.

Biochem/physiol Actions

Cetrorelix acetate is a luteinizing hormone releasing hormone receptor antagonist. It causes prepubertal reduction in bone modeling, bone density and bone strength comparable to post-menopausal bone loss.

InChI:InChI=1/C70H92ClN17O14.C2H4O2/c1-39(2)31-52(61(94)82-51(15-9-28-77-69(73)74)68(101)88-30-10-16-58(88)67(100)79-40(3)59(72)92)83-60(93)50(14-8-29-78-70(75)102)81-63(96)54(34-43-20-25-49(91)26-21-43)86-66(99)57(38-89)87-65(98)56(36-45-11-7-27-76-37-45)85-64(97)55(33-42-18-23-48(71)24-19-42)84-62(95)53(80-41(4)90)35-44-17-22-46-12-5-6-13-47(46)32-44;1-2(3)4/h5-7,11-13,17-27,32,37,39-40,50-58,89,91H,8-10,14-16,28-31,33-36,38H2,1-4H3,(H2,72,92)(H,79,100)(H,80,90)(H,81,96)(H,82,94)(H,83,93)(H,84,95)(H,85,97)(H,86,99)(H,87,98)(H4,73,74,77)(H3,75,78,102);1H3,(H,3,4)/t40-,50-,51+,52+,53-,54-,55+,56-,57-,58?;/m1./s1